{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toripalimab", "query": { "intervention": "Toripalimab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toripalimab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T23:26:14.462Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04387084", "title": "Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Skin Neoplasm", "Metastatic Malignant Skin Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" }, { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Toripalimab", "type": "BIOLOGICAL" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-08-12", "completion_date": "2027-08-12", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387084" }, { "nct_id": "NCT07277322", "title": "Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Liver Metastases" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Feng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-09-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277322" }, { "nct_id": "NCT07423078", "title": "Window of Opportunity in Preserving Laryngeal Function Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Matthew Spector", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2026-04-06", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07423078" }, { "nct_id": "NCT04918186", "title": "Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "BA3011", "type": "DRUG" }, { "name": "BA3021", "type": "DRUG" }, { "name": "ENB003", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2022-05-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04918186" }, { "nct_id": "NCT06679985", "title": "A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Casdozokitug", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2024-12-20", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 25, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 22 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679985" }, { "nct_id": "NCT07281716", "title": "Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "Nadunolimab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Feng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-12-01", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281716" }, { "nct_id": "NCT07209189", "title": "Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma", "Oral Cavity Cancer", "Oropharyngeal Cancer", "Laryngeal Cancer", "Sinonasal Squamous Cell Carcinoma", "HPV (Human Papillomavirus)-Associated Carcinoma", "Skull Base Tumors", "HPV 16 Positive Oropharyngeal Tumors (OPC)" ], "interventions": [ { "name": "Toripalimab + Chemotherapy", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "Chemoradiotherapy or radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2026-02-18", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209189" }, { "nct_id": "NCT06975293", "title": "STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Sarcoma", "Leiomyosarcoma", "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "STC-15 in combination with toripalimab", "type": "COMBINATION_PRODUCT" }, { "name": "STC-15 monotherapy", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "STORM Therapeutics LTD", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2025-05-05", "completion_date": "2028-06-29", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 10, "location_summary": "San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06975293" }, { "nct_id": "NCT05031494", "title": "A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "YH003", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eucure (Beijing) Biopharma Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-12-08", "completion_date": "2023-08-16", "has_results": false, "last_update_posted_date": "2025-01-06", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05031494" }, { "nct_id": "NCT06457503", "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nasopharyngeal Cancer Recurrent" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2024-11-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-01T23:26:14.462Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Irvine, California • San Francisco, California + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06457503" } ] }